A Johnson & Johnson spokesperson said there are no quality issues regarding the actual medication Simponi. Rather, a defect in the device did not allow the full dose to be delivered for self-injection. The defect was detected in Germany during quality assurance checks. In total, 165 U.S. units have been recalled, according to the report.
Read the news report about the Johnson & Johnson recall.
Read other coverage about Johnson & Johnson:
– Smith & Nephew Shares Jump After Rejecting Johnson & Johnson Acquisition
– Alphatec Holdings Names Former Johnson & Johnson CFO as New CFO
– FDA Sends Johnson & Johnson Letter of Warning
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.